Get access

Very long-term remission induced by short-term rituximab monotherapy in a patient with heavily pretreated, chronic immune thrombocytopenic purpura

Authors


Michael R. Clausen, MD, Department of Hematology, Aarhus University Hospital, Tage-Hansens Gade 2, DK-8000-Aarhus C, Denmark. Tel: +45 8949 75; Fax: +45 8949 7599; e-mail: michclau@rm.dk

Abstract

The management of patients with refractory immune thrombocytopenic purpura (ITP) may be difficult. We describe a rapid-onset very long-term remission (9 years) induced by short-term rituximab monotherapy in a 62-year-old man with treatment-refractory chronic ITP. Over a 30-year period from the original diagnosis to last follow-up, the patient needed renewed treatment twelve times within the first two decades and was subsequently brought in continuous complete remission for the last decade by a single course of rituximab. The effect of rituximab in ITP has previously been described. However, in chronic, treatment-refractory ITP occurring in elderly patients, remission rates tend to be low and of short duration.

Ancillary